Treatment of deep mycoses with liposomal amphotericin B.
Amphotericin B is the mainstay of therapy of many deep mycoses, but its use is seriously hampered by dose-limiting nephrotoxicity. In this study a liposomal formulation of amphotericin B was administered to ten patients with proven deep mycoses: invasive aspergillosis (n = 4), deep candidiasis (n = 4) and zygomycosis (n = 2). The mean daily dosage of liposomal amphotericin B was 3.0 mg/kg (range 2.5 to 4 mg/kg), the mean total dosage of liposomal amphotericin B 2,781 mg (range 87 to 5,220 mg) and the mean duration of treatment 17 days (range 3 to 33 days). Treatment with liposomal amphotericin B was associated with little nephrotoxicity and an overall survival rate of 50%. The median increase of serum creatinine from baseline levels was 0.38 mg/dl (-1.2 to 2.6 mg/dl).
Berenguer
J
J
Servicio de Microbiología Clínica y Enfermedades Infeciosas, Madrid, Spain.
Muñoz
P
P
Parras
F
F
Fernández-Baca
V
V
Hernández-Sampelayo
T
T
Bouza
E
E
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects; D008081:Liposomes; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000188:drug therapy; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology
D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B